AU2017382197B2 - Compositions and methods for inhibiting seizures - Google Patents

Compositions and methods for inhibiting seizures Download PDF

Info

Publication number
AU2017382197B2
AU2017382197B2 AU2017382197A AU2017382197A AU2017382197B2 AU 2017382197 B2 AU2017382197 B2 AU 2017382197B2 AU 2017382197 A AU2017382197 A AU 2017382197A AU 2017382197 A AU2017382197 A AU 2017382197A AU 2017382197 B2 AU2017382197 B2 AU 2017382197B2
Authority
AU
Australia
Prior art keywords
composition
mice
bacteria
seizure
muciniphila
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017382197A
Other languages
English (en)
Other versions
AU2017382197A1 (en
Inventor
Elaine Hsiao
Christine OLSON
Helen VUONG
Jessica Yano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2017382197A1 publication Critical patent/AU2017382197A1/en
Application granted granted Critical
Publication of AU2017382197B2 publication Critical patent/AU2017382197B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dairy Products (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
AU2017382197A 2016-12-20 2017-12-20 Compositions and methods for inhibiting seizures Active AU2017382197B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662436711P 2016-12-20 2016-12-20
US62/436,711 2016-12-20
US201762447992P 2017-01-19 2017-01-19
US62/447,992 2017-01-19
PCT/US2017/067548 WO2018119048A1 (en) 2016-12-20 2017-12-20 Compositions and methods for inhibiting seizures

Publications (2)

Publication Number Publication Date
AU2017382197A1 AU2017382197A1 (en) 2019-07-04
AU2017382197B2 true AU2017382197B2 (en) 2022-12-01

Family

ID=62627881

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017382197A Active AU2017382197B2 (en) 2016-12-20 2017-12-20 Compositions and methods for inhibiting seizures

Country Status (7)

Country Link
US (3) US11129858B2 (enExample)
EP (1) EP3558329B1 (enExample)
JP (1) JP7166280B2 (enExample)
CN (2) CN119033822A (enExample)
AU (1) AU2017382197B2 (enExample)
CA (1) CA3047397A1 (enExample)
WO (1) WO2018119048A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119033822A (zh) 2016-12-20 2024-11-29 加利福尼亚大学董事会 用于抑制癫痫发作的组合物和方法
JP6840272B2 (ja) * 2017-06-14 2021-03-10 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
JP7520820B2 (ja) * 2018-09-20 2024-07-23 イェダ リサーチ アンド ディベロップメント カンパニー リミテッド 筋萎縮性側索硬化症の治療方法
CN113164527A (zh) * 2018-09-27 2021-07-23 芬奇治疗控股有限责任公司 用于治疗癫痫和相关障碍的组合物和方法
KR102340392B1 (ko) * 2018-10-08 2021-12-17 한국생명공학연구원 우울증의 예방 또는 치료 효과를 가지는 장내 미생물 및 이의 용도
CN110227085A (zh) * 2019-07-16 2019-09-13 江苏省中医院 Akkermansia Muciniphila在制备抗抑郁药物或者保健品中的应用
CN115916227A (zh) * 2020-06-12 2023-04-04 森永乳业株式会社 线粒体功能改善用组合物
CN113367328B (zh) * 2021-06-11 2023-02-21 无锡市人民医院 一种调节肠道菌群和能量代谢的多阶段生酮饮食配方
EP4373502A1 (en) * 2021-07-20 2024-05-29 Université catholique de Louvain Prevention and/or treatment of reward dysregulation disorders
WO2023001368A1 (en) * 2021-07-20 2023-01-26 Université Catholique de Louvain Prevention and/or treatment of reward dysregulation disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160143962A1 (en) * 2014-11-25 2016-05-26 Epiva Biosciences, Inc. Probiotic compositions containing clostridiales for inhibiting inflammation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
WO2014075745A1 (en) * 2012-11-19 2014-05-22 Université Catholique de Louvain Use of akkermansia for treating metabolic disorders
CA2940226A1 (en) * 2013-02-22 2014-08-28 The Regents Of The University Of California Compositions and methods for promoting growth of beneficial microbes to treat or prevent disease or prolong life
KR101445243B1 (ko) * 2014-03-28 2014-09-29 서울대학교산학협력단 장내 세균의 군집과 기능의 변화를 이용한 대사성 및 염증성 질환의 조기진단
KR20180010237A (ko) * 2015-05-21 2018-01-30 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 건강 증진을 위한 박테리아 집단
PT3297644T (pt) 2015-05-22 2022-03-30 Univ Arizona State Métodos para tratar distúrbios do espetro do autismo e sintomas associados
CN119033822A (zh) 2016-12-20 2024-11-29 加利福尼亚大学董事会 用于抑制癫痫发作的组合物和方法
US20220184084A1 (en) 2019-03-18 2022-06-16 The Regents Of The University Of California Compositions and methods for treating cushing's disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160143962A1 (en) * 2014-11-25 2016-05-26 Epiva Biosciences, Inc. Probiotic compositions containing clostridiales for inhibiting inflammation

Also Published As

Publication number Publication date
WO2018119048A1 (en) 2018-06-28
EP3558329B1 (en) 2024-01-31
US20200384037A1 (en) 2020-12-10
US11129858B2 (en) 2021-09-28
CA3047397A1 (en) 2018-06-28
AU2017382197A1 (en) 2019-07-04
US20240238350A1 (en) 2024-07-18
CN119033822A (zh) 2024-11-29
EP3558329C0 (en) 2024-01-31
EP3558329A1 (en) 2019-10-30
CN110325196B (zh) 2024-08-27
JP7166280B2 (ja) 2022-11-07
US12364717B2 (en) 2025-07-22
US11883441B2 (en) 2024-01-30
US20220184144A1 (en) 2022-06-16
JP2020502281A (ja) 2020-01-23
CN110325196A (zh) 2019-10-11
EP3558329A4 (en) 2020-07-22

Similar Documents

Publication Publication Date Title
US12364717B2 (en) Compositions and methods for inhibiting seizures
US12292445B2 (en) Methods of selecting subjects for treatment with metabolomic modulators
Olson et al. The gut microbiota mediates the anti-seizure effects of the ketogenic diet
CN116033835B (zh) 用于改善代谢健康的包含细菌菌株的组合物
JP2018513196A (ja) マイクロバイオーム制御因子及び関連するその使用
US12491217B2 (en) Compositions and methods for promoting healthy neural development in an unborn baby
US20220265733A1 (en) Compositions comprising bacterial strains
WO2025038777A2 (en) Probiotics and methods to reduce appetite
US20220218762A1 (en) Compositions and methods for modulating cognitive behavior
WO2024187244A1 (en) Microbiota compositions and methods for treating disorders
US20250025516A1 (en) Compositions and methods for inhibiting seizures
WO2021016347A1 (en) Compositions and methods for treating skin infections and other diseases
Favaron et al. The ageing microbiome, pharmaceutical considerations, and therapeutic opportunities
US20240293344A1 (en) Unsaturated Hydroxamic Acid Derivatives and Their Use for the Treatment and Prevention of an Ammonia-Associated Disease or Disorder
EP3517119A1 (en) Composition comprising new lactobacillus salivarius strain and method for the prevention and treatment of otitis and upper respiratory infections
WO2025189253A1 (en) Microbiota compositions and methods for treating disorders
US20250228909A1 (en) Therapeutic compositions and methods
CN121175059A (en) Microbial flora
CN118215491A (zh) 通过植物乳杆菌进行的谷氨酸盐消耗和gaba形成
NZ760637B2 (en) Compositions comprising bacterial strains

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)